WASHINGTON — Medicare has begun providing coverage for certain GLP-1 weight-loss medications through a new nationwide pilot program, marking the first time eligible beneficiaries can obtain federal coverage for obesity treatment without qualifying through another approved medical indication.
The Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge demonstration on July 1, allowing eligible Medicare Part D beneficiaries to receive selected anti-obesity drugs for a fixed $50 monthly copayment. The temporary program is scheduled to run through Dec. 31, 2027, while federal officials evaluate clinical outcomes, utilization and costs before considering longer-term policy options.
The demonstration covers specified formulations of Novo Nordisk's Wegovy, Eli Lilly's Zepbound KwikPen and Foundayo for patients who meet CMS eligibility requirements. The program operates outside the standard Medicare Part D benefit, with CMS administering prior authorization, claims processing and payments through a centralized system.
According to CMS, beneficiaries generally qualify if they have Medicare Part D coverage and meet body mass index thresholds tied to obesity or overweight accompanied by certain cardiovascular or metabolic risk factors. Patients already receiving Medicare coverage for GLP-1 drugs because of conditions such as Type 2 diabetes are not eligible for the Bridge program, as those prescriptions continue to be handled through existing Medicare benefits.
The initiative represents a significant policy shift because federal law has long limited Medicare coverage of medications prescribed solely for weight loss. Previous Medicare coverage of GLP-1 medicines has generally been restricted to approved indications such as diabetes or cardiovascular risk reduction.
CMS has said the demonstration is intended to expand access while gathering evidence on whether broader coverage can improve health outcomes and provide value for the Medicare program. The agency announced the initiative in May, describing it as a short-term demonstration authorized to test alternative payment approaches.
Physicians and obesity specialists have welcomed broader access for eligible patients but have also raised concerns about implementation and long-term continuity. Some experts have cautioned that older adults using GLP-1 medications require careful monitoring because treatment may contribute to loss of muscle mass and bone density if not accompanied by appropriate nutrition and resistance exercise. Others have questioned what will happen after the demonstration expires if Congress does not authorize permanent Medicare coverage for obesity medications.
Industry analysts have said the near-term financial impact on drug manufacturers is likely to be limited because eligibility criteria remain narrower than the medicines' FDA-approved indications and participation is expected to be constrained during the pilot program.
